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vaccination in primary care practices:
a mixed methods study using the
Consolidated Framework for
Implementation Research
Jane M. Garbutt1*, Sherry Dodd2, Emily Walling2,3, Amanda A. Lee4, Katharine Kulka2 and Rebecca Lobb4
Abstract
Background: In the United States, the effective, safe huma papilloma virus (HPV) vaccine is underused and
opportunities to prevent cancer continue to be missed. National guidelines recommend completing the 2–3 dose
HPV vaccine series by age 13, well before exposure to the sexually transmitted virus. Accurate characterization of
the facilitators and barriers to full implementation of HPV vaccine recommendations in the primary care setting
could inform effective implementation strategies.
Methods: We used the Consolidated Framework for Implementation Research (CFIR) to systematically investigate
and characterize factors that influence HPV vaccine use in 10 primary care practices (16 providers) using a concurrent
mixed methods design. The CFIR was used to guide collection and analysis of qualitative data collected through in-person
semi-structured interviews with the primary care providers. We analyzed HPV vaccine use with data abstracted from
medical charts. Constructs that most strongly influenced vaccine use were identified by integrating the qualitative and
quantitative data.
Results: Of the 72 CFIR constructs assessed, seven strongly distinguished and seven weakly distinguished between
providers with higher versus lower HPV vaccine coverage. The majority of strongly distinguishing constructs were
facilitators and were related to characteristics of the providers (knowledge and beliefs; self-efficacy; readiness for
change), their perception of the intervention (relative advantage of vaccinating younger vs. older adolescents), and
their process to deliver the vaccine (executing). Additional weakly distinguishing constructs that were facilitators were
from outer setting (peer pressure; financial incentives), inner setting (networks and communications and readiness
for implementation) and process (planning; engaging, and reflecting and evaluating). Two strongly distinguishing
constructs were barriers to use, one from the intervention (adaptability of the age of initiation) and the other from
outer setting (patient needs and resources).
Conclusions: Using CFIR to systematically examine the use of this vaccine in independent primary care practices
enabled us to identify facilitators and barriers at the provider, interpersonal and practice level that need to be
addressed in future efforts to increase vaccine use in such settings. Our findings suggest that implementation
strategies that target the provider and help them to address multi-level barriers to HPV vaccine use merit further
investigation.
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Background
A vaccine targeting oncogenic human papilloma viruses
(HPV) is an important health innovation. The HPV
vaccine is predicted to prevent ~ 70% of cervical cancers
as well as other genitourinary and oral cancers and
genital warts in men and women. [1, 2] The vaccine has
been recommended for routine use in the United States
for over ten years [1] and already has been shown to
prevent up to 99% of HPV-related cervical dysplasia, a
precursor of cervical cancer. [1–3] However, the full
benefit of the HPV vaccine can only be realized if the
vaccination series is completed prior to exposure to the
sexually transmitted virus. National guidelines recom-
mend giving the vaccine to all adolescents at their 11 to
12 year old check-up visit concurrently with the tetanus,
diphtheria, pertussis booster (Tdap) and the meningo-
coccal conjugate vaccine (MCV4), and completing the
HPV vaccine series before their 13th birthday. [4] Until
a few months ago, the recommended series comprised 3
doses given over 6 months. At the end of 2016, this
changed to 2 doses of the 9-valent vaccine given over 6
to 12 months, if the series is initiated before the 15th
birthday. [5]
Introduced in the United States (U.S.) for girls in 2006
and for boys in 2011, use of this effective vaccine is far
below the Healthy People 2020 objective of 80% cover-
age by age 13 to 15 for both sexes. [6] In 2015, only 41.
9% of eligible females and 28.1% of eligible males aged
13–17 years had completed the 3-dose series, with
marked variation among states. [7] Opportunities to pre-
vent cancer continue to be missed. There is an obvious
disparity in uptake of HPV vaccine when compared with
coverage for Tdap (86.4%) and MCV4 (81.3%) in the
same age-group. [7] Interventions to increase initiation
of the HPV vaccine and series completion targeting both
parents and providers that have been rigorously evalu-
ated, have had at best a modest effect (~ 5% increase).
[1, 8], [9] Many studies showing larger effects have been
criticized for being methodologically deficient. [1, 9, 10]
Alternative approaches to increase use of HPV vaccine
are urgently needed. Accurate characterization of the
facilitators and barriers to full implementation of HPV
vaccine recommendations in the primary care setting
could inform effective implementation strategies.
Closing the gap between the national goal and
current vaccine use requires improved uptake in
primary care settings where the majority of children are
vaccinated. We hypothesized that in these settings,
factors that influence HPV vaccine use are multifactor-
ial and complex. The objective of this study was to use
a systematic approach based on the Consolidated
Framework for Implementation Research (CFIR) [11] to
identify and characterize factors that are facilitators of
and barriers to implementation of the national
recommendations for HPV vaccine use. We will use
this information to inform development of a pragmatic
and effective implementation strategy to increase timely
use of this important oncogenic vaccine.
Methods
We assessed the implementation of HPV vaccine in
ten community pediatric offices using a concurrent
mixed methods design. Quantitative and qualitative
data were analyzed separately and then were inte-
grated to provide additional information. [12] Specif-
ically, we conducted a retrospective analysis of HPV
vaccine use data abstracted from medical charts and
acquired during in-person semi-structured interviews
with the pediatric primary care providers. The study
was approved by the Washington University Human
Research Protection Office.
The CFIR was used to guide development of the inter-
view guide, data coding, and data analysis. Damschroder
and colleagues developed the CFIR to consolidate and
unify key constructs from 19 published implementation
theories. [11] Seventy-two constructs are grouped under
five major domains that influence successful implemen-
tation of evidence-based interventions. These include
characteristics of the intervention (in this case, use of
HPV vaccine in accordance with CDC guidelines), the
inner setting (the pediatric practice), the outer setting
(the context in which the pediatric practice resides),
individual characteristics of the implementers (the
healthcare providers), and the processes used for imple-
mentation of the intervention. [11] Definitions of the
constructs within each domain can be found at 13012_
2008_182_MOESM3_ESM.pdf [11].
Study participants
We invited all members of the Washington University
Pediatric and Adolescent Ambulatory Research Consortium
(WU PAARC) to participate. WU PAARC is a practice-
based research network of 79 community pediatricians and
6 pediatric nurse practitioners associated with Washington
University. A convenience sample of 16 providers from ten
practices volunteered to participate. Each participant pro-
vided written consent and received $50 as a token of appre-
ciation for their time.
Advisory board
The study was guided by an Advisory Board of three
pediatricians, one pediatric nurse practitioner, and two
parents. The three pediatricians volunteered to be study
subjects. The group met five times over the 12-month
study period to review materials, problem solve, and
assist in interpretation of study findings.
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Data collection
Quantitative data
For each provider, we abstracted data on vaccine cover-
age from medical charts for girls and boys who were 11
to 15 years old and had attended at least one office visit
between January 1st, 2014 and December 31st, 2014.
Data abstracted from the chart included: gender, date of
birth, date of vaccine and type of vaccine (HPV, Tdap
and MCV4).
Qualitative data
We developed an interview guide with a series of open-
ended questions and probes to elicit examples that
would clarify and illustrate the participant’s responses.
The guide included general and specific questions that
addressed the main CFIR constructs to determine those
that supported or created barriers to implementation.
We explored how each of these constructs differed from
that used for other adolescent vaccines to gather infor-
mation to explain the higher coverage for the other
childhood vaccines. The interviews were conducted be-
tween 1/27/2016 and 5/24/2016, by the principal investi-
gator (JG) and co-investigator (EW). Interviews were
designed to last about 30 min and were conducted at
the practices. All were digitally recorded and transcribed
verbatim by trained transcriptionists. After the qualita-
tive interview, participants completed a short, structured
survey describing their practice arrangements.
Data analysis
Quantitative data
For each practice and provider, we computed the overall
coverage with HPV vaccine as the percentage of girls and
boys who received three doses by their 13th birthday (a
HEDIS measure for adolescent care). [13]
Qualitative data
We used a deductive approach to coding guided by the
CFIR domains and constructs. We were also open to
new themes that emerged inductively from the data. The
transcripts were organized using NVivo software and
each transcript was analyzed using consensual qualitative
research methods with multiple analysts from diverse
disciplines (e.g. pediatrician, implementation scientist,
health services researcher) to foster multiple perspec-
tives and validation. [14] We used an iterative process to
develop a codebook that reflected each CFIR domain
and its constructs, and key themes that emerged by
refining the code definitions through consensus. The
coding process began with two analysts who independ-
ently reviewed each transcript to identify the text units
that were associated with each of the CFIR domains.
Subsequently, they compared assessments, discussed
differences and came to agreement on final text assign-
ments. The text within each CFIR domain was further
coded by three analysts to identify constructs within
each CFIR domain. Thus, each transcript was subjected
to a two-level consensus process.
Rating the CFIR constructs
Each transcript was subjected to a rating process. Five
analysts used a deliberated consensus process to assign a
rating to each construct within each transcript. The rat-
ings reflected the valence (positive or negative influence)
of the construct on implementation of HPV vaccine
according to national guidelines (3 doses completed by
the 13th birthday). Table 1 provides the criteria used to
guide the rating process.
Integrating the rating of CFIR constructs and coverage rates
Next, for each provider, we integrated their construct
ratings with their HPV vaccine coverage in a table (An
example is provided in Table 2). We grouped physicians
by coverage rates using tertiles: lower coverage < 5% (n
= 5 providers), moderate coverage 6–19% (n = 6), and
higher coverage > 20% (n = 5). This approach allowed
us to observe patterns of ratings for CFIR domains and
constructs among lower and higher coverage providers
and generate hypotheses about constructs that distin-
guished between groups. We focused on extreme values
of coverage to ascertain the most information. [14]
Strongly and weakly distinguishing patterns were deter-
mined based on two dimensions within and across
higher and lower coverage groups. We first assessed the
pattern of positive and negative ratings for each
construct within coverage groups (higher and lower) to
determine if the factor was a facilitator or barrier to use
of HPV vaccine. Next, we examined the difference in
Table 1 Criteria Used to assign Ratings to Constructs
Rating Criteria
-1 A negative influence on providing HPV vaccine according to guideline recommendations i.e., complete the 3-dose series by the child’s 13th
birthday. The interviewee provides examples of how key aspects of the construct exert a negative impact on HPV vaccine use, reports an
overall negative effect, or sufficient information is provided to make indirect inference about a negative effect.
O Appears to have no effect on use of HPV vaccine according to guideline recommendations.
+ 1 A positive influence on providing HPV vaccine according to guideline recommendations i.e., complete the 3-dose series by the child’s 13th
birthday. The interviewee provides examples of how key aspects of the construct exert a positive impact on HPV vaccine use, reports an
overall positive effect, or sufficient information is provided to make indirect inference about a positive effect.
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positive or negative ratings in the higher and lower
coverage groups to determine if the construct was an
important distinguishing factor. If this difference was ≥
60% (e.g.,5/5 or 100% positive in higher coverage and
1/5 or 20% positive in lower coverage), the construct
was considered to be “strongly distinguishing.” If this
difference was between 40% to 59% (e.g., 5/5 or 100%
positive in higher coverage and 3/5 or 60% positive in
lower coverage), the construct was considered to be
“weakly distinguishing.” If the difference was < 40% (e.g.
,5/5 or 100% positive in higher coverage and 4/5 or
80% positive in lower coverage), the construct was de-
termined to provide limited information about coverage
rates. To support the validity of our conclusions, we
checked with members of the Advisory Board. [14]
Results
Sixteen providers participated in both the quantitative and
qualitative studies. They comprised 15 pediatricians and
one pediatric nurse practitioner. Five were male, 11 were
female, 13 were Caucasian, 2 were African American, and
one was Asian. The 16 providers were drawn from ten
practices, nine of which had multiple providers (2–6
providers per practice). Two practices were part of a
healthcare group and had access to central support for
information systems and quality improvement staff. Such
resources were not available at other practices. Eight prac-
tices used an electronic medical record (EMR).
Quantitative data
Medical records from a total of 4592 teens were eligible
for inclusion in the data analysis of coverage rates. Over-
all, 13.9% of eligible teens had received 3-doses of HPV
vaccine before their 13th birthday (16.9% girls, 11.3%
boys). This metric varied among practices from 2.3% to
25.5% and there was wide variability in HPV vaccine
coverage among providers within the same practice
(Table 3). Consequently, we chose to analyze the qualita-
tive data at the level of the individual provider rather
than at the level of the practice.
Qualitative data
CFIR constructs are not reported if we found limited text
that could be coded within that domain construct. For
intervention domain, this included the following con-
structs: intervention source, evidence strength and quality,
trialability, design quality and packaging. For the inner
setting domain, this included: structural characteristics,
culture, compatibility, organizational incentives and
rewards, and learning climate. For the characteristics of
individuals domain, we found no text about individual
identification with the organization. Within the process
domain, we did not identify any opinion leaders, internal
implementation leaders or champions.
Innovation characteristics domain
Relative advantage
The most commonly mentioned perceived advantages to
providing HPV vaccine at age 11–12 years rather than to
older teens were increased immunogenicity, successfully
completing the series before exposure to HPV and
accessing the child at their 11–12 year old check-up
required by school. Although the vaccine can be given
to children as young as 9, no providers did so routinely.
Several providers offered it to younger children accom-
panying an older sibling to a check-up visit where they
received HPV vaccine.
Table 2 An example of the table of integrated data from qualitative and quantitative studies comparing ratings for CFIR constructs
in the characteristics of individuals domain and HPV vaccine coverage data (completion of 3 doses by 13th birthday)
CHARACTERISTICS OF INDIVIDUALS 1013 1004 1007 1015 1005 1001 1009 1020 1019 1008 1014 1018 1010 1006 1011 1003
HPV vaccine coverage 25.5% 24.6% 24.0% 23.0% 20.5% 18.1% 16.5% 16.1% 8.7% 8.1% 6.1% 4.8% 4.6% 4.2% 3.7% 1.2%
Knowledge and Beliefs
Value completing the
vaccine by age 13
+ + + + + + + – + + + – – – + –
Believes benefit in bundling + + + + + + + – + + – + + – + –
Self-Efficacy
Enthusiastic use of HPV vaccine + + + + + + + + + + + + + – + –
Familiarity with facts about HPV
vaccine
+ + + + + + + + + + + + + – + +
Confident to recommend
strongly at early age (11–12)
+ + + + + + + + + + + – – – + –
Confident in ability to convince
hesitant parents
+ – + + + – + + + + – – – – + –
Readiness to change + – + + + – + – – – + – – – + –
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Adaptability
All providers adapted the vaccine dosing schedule, most
often to provide the 2nd and 3rd doses at subsequent an-
nual checkup visits. Some providers also delayed the age of
initiation beyond 11–12 years to prevent teens from having
three vaccines concurrently or to avoid conflict with a fam-
ily they thought might be uncomfortable discussing pre-
vention of a sexually transmitted disease at this age.
Complexity
The majority of providers identified at least one diffi-
culty with administering the 3-dose series. Many cited
the resistance and hesitancy of parents, as exemplified
by this quote:
“Well, I think you have to go in more proactively with
that one [HPV], because you expect a fight. You do,
because nine times out of ten, you have a parent who
has heard something about it who has a problem with
it. You are trying to push the vaccine in a positive way
before the negative parts come in from the parent.”
Others mentioned that it took longer to discuss HPV
vaccine than other adolescent vaccines and less frequent
visits of older adolescents increased the difficulty of
completing the series.
Cost
Few providers mentioned cost associated with providing
HPV vaccine, although several noted that providing the
3-dose series was revenue generating.
Outer setting domain
Patient needs and resources
Most providers felt it was important to provide informa-
tion about vaccine benefits as reported by this provider:
“I think there are a lot of negative messages out there,
so it’s important for the families to hear the positive
message from us.”
To address this need, they routinely informed parents
that HPV vaccine prevents cancer and sometimes they
mentioned the prevention of warts. However, few routinely
discussed vaccine safety, preferring to provide this informa-
tion if parents expressed specific safety concerns. Few used
parent educational materials apart from the required
vaccine information sheets (VIS) from the CDC. Several
providers noted that teenagers often were concerned about
getting the HPV vaccine as they had heard it was more
painful than other vaccines, and some teens were reluctant
to get all three adolescent vaccines at the same visit.
Peer pressure
A few providers described pressure from a partner in
their practice to change their approach to HPV vaccine
implementation.
External policy and incentives
All providers were aware of the national guideline
recommendations to complete the 3-dose series by age
13. Many parents chose to defer HPV vaccine as it is not
required for school attendance. Few providers were
aware of financial incentives including those offered by
vaccine manufacturers to increase completion of the 3-
dose series and by Medicaid to promote meaningful use
of clinical information.
Cosmopolitan
All providers reported that they learned about the recom-
mendations for HPV vaccine from external sources, most
commonly through membership with the American
Academy of Pediatrics (AAP) list serve. They also received
Table 3 Coverage Rates for HPV Vaccine by Practice and Provider
Practice Number of children age 13 Electronic medical record (EMR) or paper records Completed 3 doses HPV by 13th birthday
Practice coverage Provider coverage
A 329 EMR 25.5% 25.5%
B 383 EMR 23.0% 23.0%
Ca 299 EMR 18.1% 18.1%
D 726 EMR 18.6% 24.0%, 3.7%
E 441 Paper records 13.8% 24.6%, 16.1%, 4.2%
Fa 940 EMR 10.6% 20.5%, 4.6%
G 636 EMR 9.6% 16.5%, 8.1%
H 416 EMR 8.7% 8.7%
I 293 EMR 6.1% 6.1%
J 129 Paper records 2.3% 4.8%, 1.2%
All 4592 13.9%
aPractice was part of a healthcare group with access to information system assistance and quality improvement staff
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information from “throw away” medical journals, drug
representatives, and the internet, and were unlikely to seek




Except for the solo-practitioner, all providers reported
formal or informal opportunities for communication
with other providers in their practice, typically through
formal meetings or shared office space. However, the
majority of providers were unaware of how their col-
leagues approached delivery of HPV vaccine.
Readiness for implementation
Few providers reported leadership engagement in
system-level improvement activities or use of available
resources (such as their EMR and reminder calls) to in-
crease use of HPV vaccine. Only one provider reported
training for office staff involved with vaccine delivery.
Implementation climate
In some practices that delivered both the other adoles-
cent vaccines at the 11–12 year old check-up visit, deliv-
ery of HPV vaccine fit well with existing workflows. In
others, delivery required additional work at a subsequent
check-up visit. More than half of providers reported that
increasing use of HPV vaccine was a relatively high
priority for improvement within their practice, but there
were no statements that demonstrated a tension for
change. Although all aspired to 100% vaccine coverage,
none had any formal goals for themselves or their prac-
tice, or monitored vaccine coverage.
Characteristics of individuals domain
Knowledge and beliefs
All providers believed that HPV vaccine was an important
vaccine and had a personal investment in providing the
vaccine. Several routinely provided vaccine-related facts
about HPV vaccine to parents such as usage data to
address safety concerns. The majority of providers were
aware that earlier vaccination resulted in an increased
immune response. They varied in their belief that the vac-
cine should be initiated at age 11–12 years, and that there
was benefit to initiating the HPV series by bundling with
Tdap and MCV4. While some were very supportive of this
“bundling,” others thought it was “a harder sell.” Several
providers were reluctant to immunize pre-pubertal teens
and tailored their recommendation to their perception of
the child’s risk of sexual activity. One provider mentioned
concern that the duration of protection may not be
adequate if provided at age 11–12.
Self-efficacy
Providers varied in their confidence to strongly recom-
mend HPV vaccine at the 11–12 year visit and to convince
hesitant parents to accept it. Many expressed frustration
with hesitant parents as demonstrated by this quote:
“You can talk until you’re blue in the face and give
every ounce of evidence and research behind what
you do and why you do it. They don’t listen. It
just—it’s frustrating as a provider. Extremely
frustrating.”
Readiness to change
Several providers had engaged in informal efforts to
change their approach to increase vaccine use. An
example is described by this provider.
“I used to say, “I have an optional vaccine.” And, I
found that when I said that, I had a very, very low,
um, percentage of patients who agreed to take it.
So, I don’t use the word ‘optional’ anymore.”
Process domain
Planning
No-one used a formal planning process initially to imple-
ment HPV vaccine or subsequently to change their
approach to vaccine use.
Engaging
Few providers had actively engaged staff members in
problem solving to increase vaccine use or expected their
Medical Assistants (MAs) to endorse vaccination.
“[The MA’s] don’t really influence the parents’
decisions about vaccines…They administer the
vaccines, but they’re not counseling.”
Executing
Providers universally assumed responsibility for vaccine
delivery and reported the same approach for girls and
boys. Typically, they recommended the HPV vaccine at
the 11–12 year old visit, although the strength of this
recommendation varied. Some providers routinely shared
personal information about vaccinating their children or
grandchildren, while others only provided this information
if asked. One provider had the MA present all three
vaccines as “the vaccines recommended today,” and only
discussed benefits and concerns if requested by the parent.
He suggested that this MA-driven process of presenting
this vaccine as “no different from any other vaccine” was
very effective. He thought that the more traditional
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approach of “We’re gonna do this vaccine today, this
vaccine today, and your doctor will discuss this vaccine
with you today. …” both “justified the concern that fam-
ilies have if they came in with it and it created concern in
families that didn’t.”
Teamwork to deliver the vaccine series was uncommon.
Many providers were unaware of the approach their MA
took with parents regarding follow-up doses after they
had immunized them with the first dose.
All providers reported that they had vaccine-only visits
and offered follow-up doses at acute care visits. Few
used practice-level strategies to support subsequent
doses such as routinely booking follow-up appointments
or making reminder calls to parents. Most often the
responsibility to schedule the 2nd and 3rd doses was left
to the parent.
Reflecting and evaluating
No providers reviewed HPV vaccine coverage data. One
provider commented that, “it’s not as easy as you think
to get the data out of here [the EMR].”
Integrated data results
Of the 72 CFIR constructs assessed in the table with
the coverage rates, seven strongly distinguished and
seven weakly distinguished between providers with
higher versus lower HPV vaccine coverage. These
constructs are briefly described here and are summa-
rized in Table 4 as facilitators and barriers to vaccine
use.
Intervention characteristics domain
Within the intervention characteristics domain, relative
advantage and adaptability of the age of initiation were
strongly distinguishing constructs, one acting as a facili-
tator and one as a barrier to vaccine use. All providers
in the higher coverage group had positive ratings for
perceiving a relative advantage to providing the vaccine
at age 11–12 years as suggested by the guidelines com-
pared to delaying until the teen is older, as characterized
in this quote.
“We would recommend the Tdap, the Menactra,
as well as the HPV. …We recommend starting the
HPV at that age, simply because the earlier you start
it, the more effective it becomes. You want to start
it because you want to get the kids before there’s any
concern for any exposure. You wanna make sure that
they complete their series. We always routinely
recommend that at 11.”
Table 4 Facilitators and Barriers for completing the HPV vaccine series by 13th birthday
CFIR Domain Facilitators Barriers
Characteristics of HPV vaccine
recommendations
*Perceived advantage to vaccinate at age 11/12
compared to older:
• Increased immunogenicity
• Efficient; Can bundle
• Complete series before exposure
• Easier patient access
*Adapt recommendation to initiate
at older age
External environment and context Financial incentives for series completion:
• Increased billing
• Meaningful use for Medicaid
*Not mandated by school therefore
offer as optional at age 11/12
Internal context of practice • Communication across staff and providers to
coordinate series completion
• Leadership engaged in system level improvements
e.g., EMR
• Use of multiple available resources e.g., EMR alert,
outreach calls
Characteristics and attitudes of providers • *Perceive value in completing series by age 13
• Perceive value in bundling 3 adolescent vaccines
• *Confident to strongly recommend HPV vaccine
and to convince hesitant parents
• Enthusiastic about HPV vaccine
• *Already made efforts to increase HPV vaccine use
Process for implementation of HPV vaccine
recommendations
• *Routinely provide strong recommendation for HPV
vaccine at age 11/12 and bundle 3 vaccines
• Involve staff in meaningful problem-solving
• Reflect on HPV vaccine use with a view to making
changes
*Strongly distinguishing factor
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None of the providers with higher coverage routinely
adapted the recommended age of vaccine initiation. Pro-
viders with lower coverage routinely initiated the vaccine
series at a later age when they described the parents as
“more accepting.”
Outer setting domain
Within the outer setting domain, patient needs and re-
sources was a strongly distinguishing construct. Providers
who anticipated that parents wanted to know which
vaccines offered at the 11–12 year old checkup were
mandatory for school attendance routinely suggested
HPV vaccine as optional at that visit. These providers also
had lower vaccine coverage suggesting this construct is a
barrier to HPV vaccine use. One provider described her
typical approach:
“Because the Menactra is, and the Tdap are required
by school, I guess I introduce them by saying these
are the vaccines they get at 11, in order to go to
school. The other one I say we highly encourage
that your child gets the HPV.”
None of the providers with higher coverage adjusted the
adolescent vaccine recommendation in this way and they
were more likely to routinely discuss vaccine safety than
those with lower coverage. Other factors in this domain
weakly distinguished between higher and lower vaccine
coverage. Providers with higher coverage were less likely
to feel peer pressure to change their implementation
approach and were more likely to have positive ratings for
responding to financial incentives as demonstrated by this
quote:
“…… we're imagining that a lot of the parameters
they're using for meaningful-use will also be for pay
for performance… and so we wanna make sure our
percentages are up there so, we're, we're always very
cognizant of those red flags (… to indicate a vaccine
is due) and, and that they need to be checked off.” …
“That, that's the main incentive. Um, you know.
Meaningful use.”
These findings suggest that a statement of vaccine
safety and awareness of financial incentives can facilitate
vaccine use.
Inner setting domain
Within the inner setting domain, patterns of ratings in the
dimensions of networks and communications and readi-
ness for implementation weakly distinguished provider-
level vaccine coverage, acting to facilitate use. Providers
who communicated with staff to coordinate vaccine use;
reported a consistent approach across providers in their
practice; described leadership engagement in system-level
improvement activities and use of available resources to
provide HPV vaccine had higher vaccine coverage than
those who did not report these features.
Characteristics of individuals domain
Within the characteristics of the individual domain,
many factors distinguished between higher and lower
vaccine coverage, all facilitating vaccine use. The know-
ledge and beliefs of the providers about HPV vaccine
was a strongly distinguishing construct. Providers with
higher coverage were more likely to believe there was
value in completing the vaccine series by age 13 and in
bundling the three recommended adolescent vaccines at
the 11–12 year checkup visit. Provider self-efficacy was a
strongly distinguishing construct as was readiness to
change of individual providers. Providers with higher
coverage were more likely to be enthusiastic and
confident in strongly recommending the vaccine at age
11–12 and in their ability to convince hesitant parents
to accept the vaccine as demonstrated by this quote:
“…I feel like I’m able to work through their concerns,
rebut any inaccuracies that they come in with, and
give them the right information they need to make
a decision to proceed.”
In contrast, those with lower coverage did not share
this confidence as demonstrated by this quote:
“…typically, if they're not going to give it, nothing
you’re going to tell them is going to change their
mind.”
Those with higher coverage were more likely to
already have engaged in personal efforts to increase
HPV vaccine use such as adding provider reminders to
the EMR.
Process domain
Within the process domain, executing was a strongly dis-
tinguishing construct. All providers with higher coverage
routinely strongly recommended and routinely provided
the vaccine at the 11–12 year old check-up visit, and bun-
dled the three adolescent vaccines. Also, they were more
likely to provide personal information about HPV vaccine
use as described by one provider:
“I give a quick spiel about how I think it’s really
important, how it helps protect against cancer, how
it’s safe, we’ve given lots of doses, nationwide lots of
doses have been given, it’s effective, it prevents cancer,
I give it to my kids and lots of kids every day, I think
it’s really important…”
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Several constructs weakly distinguished between pro-
viders with higher and lower coverage. Evidence of plan-
ning, engaging, and reflecting and evaluating was most
often associated with higher coverage, suggesting these
constructs facilitate use.
Discussion
Study findings both confirm that effective strategies to
increase HPV vaccine use are urgently needed and inform
their development. By systematically examining the com-
plex web of factors that influence use of this vaccine in
the primary care setting, we identified important facilita-
tors and barriers to following National guidelines. We
learned that a multi-level approach is needed to markedly
increase use of this important vaccine. At the provider-
level, buy-in to vaccination by age 13 is critical as is the
provider’s confidence to address parental hesitancy. At the
interpersonal-level, our findings suggest several strategies
the provider could use with the patient, parents and staff
to increase vaccine use. These include recommending the
three adolescent vaccines as a bundle and addressing par-
ental hesitation with a strong and persistent recommenda-
tion for timely HPV vaccine use. Better co-ordination
between the provider and staff who administer the vaccine
could standardize communication messages for patients
and parents and ensure opportunities for vaccination are
not missed. At the practice-level, collaboration among
providers could improve efficiency by standardizing use of
reminder systems and maximize benefit from financial
incentives.
Our findings confirm that the provider’s approach to
HPV vaccine personally, interpersonally and at the prac-
tice level, strongly influences uptake. [15, 16] Providers
in these independent community practices universally
assumed responsibility for vaccine delivery, and reported
they routinely recommended HPV vaccine, Tdap and
MCV4 to their patients at their 11–12 year-old checkup
visit. Our analysis demonstrated that the quality of their
recommendation varied widely as did HPV vaccine
coverage by age 13. These findings are consistent with
national studies with larger samples [17, 18] and likely
reflect the complexity of communication about this
vaccine. [18] Failure to require HPV vaccine for school
attendance influenced some providers to suggest that
the vaccine could be delayed [19] and anticipation of
parental resistance caused them to feel compelled to
have a conversation about the vaccine. This likely
contributed to reduced vaccine uptake as parents are
more likely to resist vaccination recommendations if the
provider uses a participatory, conversational approach
rather than a more directive approach (a presumptive or
announcement approach). [20, 21] It is likely that
providers’ lack of buy-in to vaccination by age 13 and
their low self-efficacy to address parental hesitancy
further compromised their ability to provide a strong
recommendation. At the practice-level, reminder and
recall systems that can increase vaccine series initiation
and completion, [9, 10, 22, 23] were infrequently used.
Many providers in our sample lacked resources such as
information technology (IT) support to augment their
EMR with these systems. [24]
Effective implementation strategies must help pro-
viders to change their approach to HPV vaccine. How-
ever, changing provider behavior is difficult. Educational
interventions targeting providers have not been success-
ful, [9] and reminders and audit and feedback have had
mixed results. [9] Although lack of a strong provider
recommendation is reputed to be the most common
barrier to use of HPV vaccine, [15–17, 25] few studies
have tried to improve the quality of provider communi-
cation. One randomized trial conducted in the primary
care setting showed that training providers to use an
announcement approach increased vaccine coverage by
5%, [8] but the broader literature of message framing
has yielded mixed results. [18] In addition to changing
provider behavior regarding the timing and quality of
their recommendation for HPV vaccine, our findings
suggest the need for providers to develop an adolescent
vaccine delivery system. While a systematic approach
was effective in a large healthcare system with access to
staff and technical support for implementation, [19]
most interventions to systematize vaccination in primary
care practices have been disappointing and expensive.
[9] [26] A recent randomized controlled trial showed an
intervention comprised of provider education, audit and
feedback and EMR reminders increased vaccine
initiation by 8% and the intervention was relatively inex-
pensive, but may not be scalable without IT support.
[27] Effective, scalable interventions to encourage and
support providers in independent practices to deliver
HPV vaccine to all eligible teens in a timely fashion are
needed. [10]
Our findings inform an implementation strategy to
change provider behavior regarding this complex vac-
cine. An acceptable approach will be simple to use, save
time, and alleviate the stress associated with dealing with
vaccine hesitant parents. [28] Key ingredients might
include the following: 1) Education to motivate behavior
change and increase self-efficacy. Providers must be con-
vinced of the benefits of early initiation of the vaccine
series and able to succinctly and comfortably address
parental concerns. 2) To facilitate change, additional
pragmatic resources such as a communication strategy
to increase the quality of vaccine recommendation are
needed. 3) Targeting increased coverage for any age
before the 15th birthday may engage more providers in
the change process and capitalize on the latest recom-
mendation for a 2-shot series. [5] It would also
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significantly impact the Healthy People 2020 goal of 80%
coverage for 13–15 year olds. 4) Finally, engaging staff in
developing and implementing a new vaccine delivery
system to increase vaccine use would be beneficial.
Failure to simultaneously address all these factors may
explain why prior interventions to improve use of HPV
vaccine have had at best a modest effect and changes
have not been sustained.
Our study is limited by several considerations. Although
we believe the study sample is representative of providers
working in independent, community-based pediatric prac-
tices in our community with considerable variation in the
context of where and how the providers practiced, our
convenience sample of 16 providers is small and from one
geographic area and may not be representative of other
populations. Completion of the 3-dose series before the
13th birthday was low among participants, consistent with
national data. [7] As no providers had high vaccine
uptake, our findings regarding barriers and facilitators for
HPV vaccine uptake should be considered as exploratory.
The time span for collecting the quantitative and qualita-
tive data were different (2014 and 2016 respectively.
National data show the increase in HPV vaccine coverage
from 2014 to 2015 was minimal, and suggest that a dra-
matic change between 2014 and 2016 is unlikely. [7, 29]
However, if changes in coverage were large and not equal
across providers, then our assessment of barriers and
facilitators may be inaccurate. Finally, our qualitative data
was retrospective and we did not interview parents or
patients.
Conclusions
In conclusion, study and national data suggest that many
teens are not protected against HPV-related cancers
prior to exposure to the virus and that widespread
efforts to increase HPV vaccine use are urgently needed.
Using CFIR to systematically examine the use of this
vaccine in independent primary care practices enabled
us to identify facilitators and barriers at the provider, inter-
personal and practice level that need to be addressed in
future efforts to increase vaccine use in such settings. Our
findings suggest that implementation strategies that target
the provider and help them to address multi-level barriers
to HPV vaccine use merit further investigation.
Abbreviations
AAP: American Academy of Pediatrics; ACIP: Advisory Committee on
Immunization Practices; CDC: Centers for Disease Control and Prevention;
EMR: Electronic Medical Record; HEDIS: Healthcare Effectiveness Data and
Information Set; HPV: Human Papillomavirus; IQR: Inter-quartile range;
MCV4: Quadrivalent meningococcal vaccine; NCATS: National Center for
Advancing Translational Sciences; NIH: National Institutes of Health;
Tdap: Tetanus, diphtheria and pertussis vaccine; U.S.: United States;
VIS: Vaccine information sheet; WU PAARC: Washington University Pediatric
and Ambulatory Research Consortium
Funding
This study was supported by the Washington University Institute of Clinical
and Translational Sciences grant UL1 TR000448 from the National Center for
Advancing Translational Sciences (NCATS) of the National Institutes of Health
(NIH), with co-funding from St. Louis Children’s Hospital. This study’s contents
are solely the responsibility of the author and do not necessarily represent
the official view of NCATS or NIH. The sponsors had no involvement in the
design and conduct of the study; collection, management, analysis, and
interpretation of the data; preparation, review, or approval of the manuscript;
and decision to submit the manuscript for publication.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated
or analyzed during the current study.
Author’s contributions
JMG designed the study, conducted interviews, analyzed and interpreted
the qualitative and quantitative data, and drafted the manuscript. SD
analyzed and interpreted the qualitative data and critically reviewed and
edited the manuscript. EW conducted interviews, analyzed and interpreted
the qualitative data, and critically reviewed and edited the manuscript. AAL
analyzed and interpreted the qualitative data, and critically reviewed and
edited the manuscript. KK analyzed and interpreted the qualitative data,
and critically reviewed and edited the manuscript. RL designed the study,
analyzed and interpreted the qualitative data, and critically reviewed and
edited the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the Washington University Human Research
Protection Office (Ref # 210510093). Each participant provided written
consent.
Consent for publication
We confirm that the consent form signed by all participants provides
consent to publish anonymous quotes within the manuscript.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Departments of Medicine and Pediatrics, Washington University School of
Medicine, St. Louis, MO, USA. 2Department of Pediatrics, Washington
University School of Medicine, Campus Box 8116, 660 S. Euclid Ave, St. Louis,
MO 63110, USA. 3Department of Pediatrics, Michigan Medicine, C.S. Mott
Children’s Hospital, Ann Arbor, USA. 4Department of Surgery, Washington
University School of Medicine, St. Louis, MO, USA.
Received: 22 August 2017 Accepted: 23 April 2018
References
1. Fu LY, Bonhomme LA, Cooper SC, Joseph JG, Zimet GD. Educational
interventions to increase HPV vaccination acceptance: a systematic review.
Vaccine. 2014;32(17):1901–20.
2. President's Cancer Panel Annual Report 2012-2013 [http://deainfo.nci.nih.gov/
advisory/pcp/annualReports/HPV/PDF/PCP_Annual_Report_2012-2013.pdf].
Accessed 30 Apr 2018.
3. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM.
Impact of a population-based HPV vaccination program on cervical
abnormalities: a data linkage study. BMC Med. 2013;11:227.
4. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini
JA Jr, Unger ER, Centers for Disease C, Prevention. Human papillomavirus
vaccination: recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30.
5. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human
papillomavirus vaccination - updated recommendations of the advisory
Garbutt et al. BMC Family Practice  (2018) 19:53 Page 10 of 11
committee on immunization practices. MMWR Morb Mortal Wkly Rep.
2016;65(49):1405–8.
6. Healthy People 2020 [http://healthypeople.gov/]. Accessed 30 Apr 2018.
7. Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Curtis CR, MacNeil J,
Markowitz LE, Singleton JA. National, regional, state, and selected local area
vaccination coverage among adolescents aged 13−17 years - United States,
2015. MMWR Morb Mortal Wkly Rep. 2016;65(33):850–8.
8. Brewer NT, Hall ME, Malo TL, Gilkey MB, Quinn B, Lathren C.
Announcements Versus Conversations to Improve HPV Vaccination
Coverage: A Randomized Trial. Pediatrics. 2017;139(1):e20161764.
9. Smulian EA, Mitchell KR, Stokley S. Interventions to increase HPV vaccination
coverage: a systematic review. Human vaccines & immunotherapeutics.
2016;12(6):1566–88.
10. Niccolai LM, Hansen CE. Practice- and community-based interventions to
increase human papillomavirus vaccine coverage: a systematic review.
JAMA Pediatr. 2015;169(7):686–92.
11. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC.
Fostering implementation of health services research findings into practice:
a consolidated framework for advancing implementation science.
Implementation science : IS. 2009;4:50.
12. Fetters MD, Curry LA, Creswell JW. Achieving Integration in Mixed Methods
Designs - Principles and Practices. Health Serv Res. 2013;48:1–23.
13. Immunization and Infectious Diseases [https://www.healthypeople.gov/2020/
topics-objectives/topic/immunization-and-infectious-diseases/objectives].
Accessed 30 Apr 2018.
14. Palinkas LA. Qualitative and mixed methods in mental health services and
implementation research. J Clin Child Adolesc Psychol. 2014;43(6):851–61.
15. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to
human papillomavirus vaccination among US adolescents: a systematic
review of the literature. JAMA Pediatr. 2014;168(1):76–82.
16. Perkins RB, Clark JA, Apte G, Vercruysse JL, Sumner JJ, Wall-Haas CL,
Rosenquist AW, Pierre-Joseph N. Missed opportunities for HPV vaccination
in adolescent girls: a qualitative study. Pediatrics. 2014;134(3):e666–74.
17. Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider
communication and HPV vaccination: the impact of recommendation
quality. Vaccine. 2016;34(9):1187–92.
18. Gilkey MB, McRee AL. Provider communication about HPV vaccination:
a systematic review. Human vaccines & immunotherapeutics. 2016;
12(6):1454–68.
19. Farmar AM, Love-Osborne K, Chichester K, Breslin K, Bronkan K,
Hambidge SJ. Achieving High Adolescent HPV Vaccination Coverage.
Pediatrics. 2016;138(5):e20152653.
20. Opel DJ, Mangione-Smith R, Robinson JD, Heritage J, DeVere V, Salas HS,
Zhou C, Taylor JA. The influence of provider communication behaviors on
parental vaccine acceptance and visit experience. Am J Public Health. 2015;
105(10):1998–2004.
21. Opel DJ, Heritage J, Taylor JA, Mangione-Smith R, Salas HS, Devere V, Zhou
C, Robinson JD. The architecture of provider-parent vaccine discussions at
health supervision visits. Pediatrics. 2013;132(6):1037–46.
22. Szilagyi PG, Albertin C, Humiston SG, Rand CM, Schaffer S, Brill H, Stankaitis
J, Yoo BK, Blumkin A, Stokley S. A randomized trial of the effect of
centralized reminder/recall on immunizations and preventive care visits for
adolescents. Acad Pediatr. 2013;13(3):204–13.
23. Tierney CD, Yusuf H, McMahon SR, Rusinak D, OB MA, Massoudi MS, Lieu
TA. Adoption of reminder and recall messages for immunizations by
pediatricians and public health clinics. Pediatrics. 2003;112(5):1076–82.
24. Wolfson D, Bernabeo E, Leas B, Sofaer S, Pawlson G, Pillittere D. Quality
improvement in small office settings: an examination of successful practices.
BMC Fam Pract. 2009;10:14.
25. Darden PM, Thompson DM, Roberts JR, Hale JJ, Pope C, Naifeh M, Jacobson
RM. Reasons for not vaccinating adolescents: National Immunization Survey
of teens, 2008-2010. Pediatrics. 2013;131(4):645–51.
26. Perkins RB, Zisblatt L, Legler A, Trucks E, Hanchate A, Gorin SS. Effectiveness
of a provider-focused intervention to improve HPV vaccination rates in boys
and girls. Vaccine. 2015;33(9):1223–9.
27. Fiks AG, Grundmeier RW, Mayne S, Song L, Feemster K, Karavite D,
Hughes CC, Massey J, Keren R, Bell LM, et al. Effectiveness of decision
support for families, clinicians, or both on HPV vaccine receipt.
Pediatrics. 2013;131(6):1114–24.
28. Kempe A, O'Leary ST, Kennedy A, Crane LA, Allison MA, Beaty BL,
Hurley LP, Brtnikova M, Jimenez-Zambrano A, Stokley S. Physician
response to parental requests to spread out the recommended vaccine
schedule. Pediatrics. 2015;135(4):666–77.
29. Laurie D, Elam-Evans DY, Jeyarajah J, Singleton JA, Robinette Curtis C,
MacNeil J, Hariri S. National, Regional, State, and Selected Local Area
Vaccination Coverage Among Adolescents Aged 13–17 Years — United
States, 2013. In: Morbidity and Mortality Weekly Report (MMWR), vol. 63.
Atlanta: Centers for Disease Control and Prevention; 2014. p. 625–33.
Garbutt et al. BMC Family Practice  (2018) 19:53 Page 11 of 11
